Author:
Lovshin Julie A.,Drucker Daniel J.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference57 articles.
1. Kreymann, B., Williams, G., Ghatei, M. A. & Bloom, S. R. Glucagon-like peptide-17–36: a physiological incretin in man. Lancet 2, 1300–1304 (1987).
2. Deacon, C. F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53, 2181–2189 (2004).
3. Drucker, D. J. The biology of incretin hormones. Cell. Metab. 3, 153–165 (2006).
4. Drucker, D. J. & Nauck, M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696–1705 (2006).
5. Deacon, C. F., Johnsen, A. H. & Holst, J. J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo . J. Clin. Endocrinol. Metab. 80, 952–957 (1995).
Cited by
560 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献